RAPT Therapeutics to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SOUTH SAN FRANCISCO, Calif., Sept. 3, 2021 – RAPT Therapeutics (Nasdaq: RAPT) announced that Brian Wong, M.D., Ph.D., President and CEO, will present at key investor conferences in September. Notably, he will speak at the Wells Fargo 2021 Virtual Healthcare Conference on September 9 at 8:00 a.m. EST and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 a.m. EST. For live webcasts and archived recordings, visit RAPT's official website. RAPT focuses on oral therapies for oncology and inflammatory diseases, advancing drug candidates targeting CCR4.
Details
News Market Reaction – RAPT
The recorded move for RAPT in the trading session of this news was +0.70%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in the first half of September:
- Wells Fargo 2021 Virtual Healthcare Conference Thursday, September 9, 2021 at 8:00 a.m. EST
- H.C. Wainwright 23rd Annual Global Investment Conference presentation available on-demand Monday, September 13, 2021 at 7:00 a.m. EST
To access the live webcasts or subsequent archived recordings of the company presentations, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
RAPT Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.